Due to health issues, this site is no longer maintained and will be shut down shortly.


MDxHealth SA operates as a molecular diagnostics company in Belgium, the Netherlands, Spain, Poland, Italy, the United States, rest of European Union, and internationally. The company develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. Its tests are based on proprietary genetic, epigenetic, and other molecular technologies, as well as assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The company's product pipeline includes tests for bladder, kidney, and other urologic cancers. Its products include ConfirmMDx, a tissue test for prostate cancer; and SelectMDx, a non-invasive urine test for prostate cancer. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.This company has ADRs that trade in the U.S. as the symbol MDXH.

0.27 EUR
As of 03/24/2023

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Index country:  Belgium
Country of incorporation:  Belgium
IPO date:  01/01/1900
Stock exchange:    Nyse Euronext - Euronext
Exchange country:   Belgium
Market cap:   0 EUR
Current dividend yield:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy